Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2019 BIO Investor Forum in San Francisco, CA

by Neumentum Pharmaceuticals | Oct 17, 2019 | In The Media, Press Releases

PALO ALTO, Calif., October 17, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO Investor Forum being held October...

Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments

by Sky Striar | Oct 10, 2019 | In The Media, Press Releases

Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics  PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...

Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019

by Sky Striar | Sep 5, 2019 | Press Releases

Neumentum’s poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view.   – Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion – Results Confirm...

Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2019 BIO International Convention in Philadelphia, PA

by admin | May 15, 2019 | In The Media, Press Releases

PALO ALTO, Calif., May 15, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO International Convention being held...

Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted

by Sky Striar | Jan 7, 2019 | In The Media, Press Releases

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain

by admin | Sep 6, 2018 | Press Releases

– Potential to be the First Continuously Infused NSAID to be Successfully Developed for Acute Post-Operative Pain in the US – NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion with the...